Publications by authors named "Z Mitrovic"
Article Synopsis
- Patients with lymphoid malignancies experience higher death and prolonged infection rates from COVID-19, with conflicting data on how different treatments affect these outcomes.
- A study of 314 patients showed that untreated or off-treatment patients had higher mortality (15-16%) compared to those on treatment (35%), while prolonged infections were notably more common in patients using anti-CD20 antibodies like obinutuzumab.
- Key risk factors for increased mortality were older age and the use of purine analogues, while treatment type didn't significantly impact death rates, indicating that treatment choices must consider these epidemiological risks.
(1) Background: This study aimed to examine the difference in efficacy and toxicity of involved-field (IFRT) and involved-site radiotherapy (ISRT) fields in infradiaphragmal aggressive non-Hodgkin lymphoma patients. (2) Methods: In total, 140 patients with infradiaphragmal lymphoma treated between 2003 and 2020 were retrospectively evaluated. There were 69 patients (49%) treated with IFRT, and 71 (51%) patients treated with ISRT.
View Article and Find Full Text PDFPurpose: Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) is a regimen used for the treatment of high-risk diffuse large B-cell lymphoma (DLBCL) designed to overcome resistance to standard R-CHOP by combining prolonged exposure of lymphoma cells to cytotoxic agents and dose-adjustment based on toxicity. Data on outcomes of older patients are scarce.
Patients And Methods: We collected data on patients with newly diagnosed high-risk DLBCL older than 60 years treated with DA-EPOCH-R.
Purpose: Data on efficacy and toxicity of infradiaphragmal radiotherapy fields in lymphoma patients are scarce. We therefore performed this retrospective study to analyse our experience with radiotherapy exclusively to infradiaphragmal fields.
Materials And Methods: we retrospectively evaluated 101 patients treated between 2003 and 2014.
Aim: To compare the outcomes of Croatian patients with mantle cell lymphoma (MCL) who started treatment in 2007 and 2008 (historical cohort) and of those who started treatment between 2015 and 2017 (recent cohort).
Methods: The historical cohort consisted of 40 patients who started treatment with rituximab in 2007 and 2008. Data on the recent cohort, consisting of 89 patients, were collected retrospectively from the electronic databases of Croatian hospitals with hematology units.